Management of cystic fibrosis (CF) patients colonized with Pseudomonas aeruginosa is challenging due to its virulence and multi-drug resistance. Ceftolozane/tazobactam (C/T) is a promising new antipseudomonal agent, and clinical data on CF are limited. We describe our experience in the use of C/T for P. aeruginosa-related pulmonary exacerbations (PE) in CF adults admitted within 2016 and 2019 at Careggi Hospital, Florence, Italy. PE was diagnosed as deterioration of respiratory function, worsening cough, and increasing of sputum. C/T was given at the dose of 3 g every 8 h. C/T was used in ten patients. Mean length of C/T treatment was 16.3 days, and tobramycin was the most frequently combined antipseudomonal agent. All patients were successfully treated although susceptibility testing on sputum sample showed C/T resistance in two cases. No adverse effects related to C/T were reported. To our knowledge this is the largest case series on CF patients treated with C/T. Clinical responses were encouraging even where C/T resistant P. aeruginosa was isolated, probably due to multiple phenotypes colonizing CF lungs. C/T could play a promising role in combination therapy against P. aeruginosa as a part of a colistin-sparing regime.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10096-021-04218-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Response Surface Methodology for Optimization of Media Components for Production of Lipase from KUBT4.
Arch Razi Inst
June 2024
Department of Biotechnology and Microbiology, Karnatak University, Dharwad (Karnataka, India).
Lipases are triacylglycerol hydrolases with various potential applications because of their different physical properties. Most lipase producers are extracellular in nature and are created using solid-state fermentation and submerged fermentation methods. The fungal, mycelial, and yeast lipases are produced using various solid substrates through the solid-state fermentation method.
View Article and Find Full Text PDFA Randomized, Double-Blind, Phase III Study in India for Comparing Efficacy, Safety, and PK of ZRC-3277 (Pertuzumab Biosimilar) With Perjeta® in Patients With HER2-Positive Metastatic Breast Cancer.
Clin Breast Cancer
October 2024
Clinical Research and Development, Zydus Therapeutics Inc, Pennington, USA.
Introduction: To evaluate the efficacy, safety, pharmacokinetics (PK), and immunogenicity of ZRC-3277 (pertuzumab biosimilar) with Perjeta® (pertuzumab) in previously untreated patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC).
Patients And Methods: This phase III, multicenter, double-blind study across 38 sites in India randomized (1:1) patients with HER2-positive MBC in either the ZRC-3277 or Perjeta® group. Both groups also received trastuzumab and docetaxel.
IgG responses against SARS-CoV-2 vaccines AZD1222 and BBV-152 and breakthrough infections among health care workers in southern India.
Heliyon
February 2024
Nitte (Deemed to be University), University Enclave, Medical Sciences Complex, Deralakatte, Mangaluru 575018, India.
IgG antibodies elicited in response to SARS-CoV-2 are critical in determining the protection achieved through vaccination. The present longitudinal study aims to assess the immune response generated through AZD1222 & BBV-152 vaccination among health care workers (HCWs) in a selected hospital. Serum IgG levels were measured approximately at 1.
View Article and Find Full Text PDFRamucirumab in Indian Patients with Advanced Gastric Cancer-Does Borderline Performance Status and Heavy Burden of Disease in Real World Practice Impact Clinical Benefit?
South Asian J Cancer
January 2022
Department of Medical Oncology, TMH, Homi Bhabha National University, Mumbai, Maharashtra, India.
Vikas Ostwal Ramucirumab is considered a standard of care as second-line therapy (CT2) in advanced gastric cancers (AGCs). The aim of this study was to assess practice patterns and outcomes with ramucirumab among Indian patients with AGCs. A computerized clinical data entry form was formulated by the coordinating center's (Tata Memorial Hospital) medical oncologists and disseminated through personal contacts at academic conferences as well as via email for anonymized patient data entry.
View Article and Find Full Text PDFInpatient Telemedicine for Neurology Consultation at Satellite Hospitals: Patient and Provider Perspectives.
Neurohospitalist
July 2022
Department of Neurology, Wake Forest University School of Medicine, Winston Salem, NC, USA.
Article Synopsis
- A novel inpatient teleneurology consultation service was implemented at an academic medical center, where patient feedback, as well as input from ordering providers and consulting neurologists, was collected to evaluate the service's effectiveness.
- A telephone survey of 25 patients revealed that 72% felt they gained a better understanding of their condition, and many appreciated being able to stay close to home.
- Both ordering providers and consulting neurologists expressed high satisfaction with the service, noting its value in patient care, with a majority indicating they would use it again, while concerns about missed diagnoses were lower among neurologists compared to providers.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!